Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Update

Lucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) was the target of a large increase in short interest in February. As of February 15th, there was short interest totalling 1,040,000 shares, an increase of 95.2% from the January 31st total of 532,700 shares. Based on an average daily volume of 531,800 shares, the days-to-cover ratio is presently 2.0 days. Approximately 4.3% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on LUCD shares. Canaccord Genuity Group restated a "buy" rating and issued a $3.00 target price on shares of Lucid Diagnostics in a research report on Thursday, November 14th. Ascendiant Capital Markets cut their price objective on Lucid Diagnostics from $7.25 to $7.00 and set a "buy" rating on the stock in a report on Monday, December 9th. Needham & Company LLC restated a "buy" rating and set a $2.50 price objective on shares of Lucid Diagnostics in a research report on Thursday, November 14th. Finally, Cantor Fitzgerald dropped their target price on Lucid Diagnostics from $3.00 to $2.00 and set an "overweight" rating for the company in a research report on Friday, November 15th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Lucid Diagnostics presently has an average rating of "Buy" and a consensus target price of $3.63.

Institutional Investors Weigh In On Lucid Diagnostics

A number of institutional investors have recently made changes to their positions in LUCD. LPL Financial LLC lifted its stake in shares of Lucid Diagnostics by 29.1% in the fourth quarter. LPL Financial LLC now owns 53,391 shares of the company's stock worth $44,000 after acquiring an additional 12,035 shares during the period. Sunbelt Securities Inc. bought a new position in Lucid Diagnostics during the 4th quarter worth approximately $67,000. Citadel Advisors LLC acquired a new position in shares of Lucid Diagnostics in the 4th quarter worth approximately $98,000. Lido Advisors LLC boosted its stake in shares of Lucid Diagnostics by 40.0% in the 4th quarter. Lido Advisors LLC now owns 140,016 shares of the company's stock valued at $115,000 after purchasing an additional 40,000 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Lucid Diagnostics by 30.9% during the fourth quarter. Geode Capital Management LLC now owns 279,504 shares of the company's stock worth $229,000 after buying an additional 65,964 shares during the period. Institutional investors own 74.01% of the company's stock.

Remove Ads

Lucid Diagnostics Stock Performance

Shares of NASDAQ:LUCD traded up $0.05 during mid-day trading on Wednesday, reaching $1.35. 991,761 shares of the company's stock were exchanged, compared to its average volume of 319,572. Lucid Diagnostics has a twelve month low of $0.63 and a twelve month high of $1.63. The firm has a market capitalization of $80.11 million, a price-to-earnings ratio of -1.18 and a beta of 1.49. The business's fifty day moving average price is $1.05 and its 200-day moving average price is $0.93.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.